153 abstracts found.
Results filter
- Year: 2015 Remove Filter
- Session type: Oral Remove Filter
Novel intrapatient dose escalation phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 in BRCA1/2 and non-BRCA1/2 mutation patients with advanced cancers
Year: 2015
Session type: Oral, Parallel sessions
1The Institute of Cancer Research, London, UK,2Royal Marsden Hospital, London, UK
Hormone Therapy for Prostate Cancer
Year: 2015
Session type: Oral, Plenary lectures
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
Protective packaging for DNA: the role of the PBAF and INO80 chromatin remodelling complexes in maintaining genome stability
Phylogenetic analysis reveals divergent modes of clonal spread and intraperitoneal mixing in high grade serous ovarian cancer
It takes a team: the importance of integration between primary care and cancer specialist care.
Year: 2015
Session type: Oral, Parallel sessions
1Ontario Institute for Cancer Research, Toronto, Canada,2University of Toronto, Toronto, Canada
Key role of AGO2 and the 8q24 amplicon in regulation of microRNA biogenesis in cancer
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1University of Oxford, Oxford, UK
Mutations in the transcriptional repressor REST predispose to Wilms tumour
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Division of Genetics & Epidemiology, Institute of Cancer Research, London, UK,2Verna & Marrs McLean Dept. of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA,3Dept of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA,4Our Ladys Childrens Hospital, Dublin, UK,5Wake Forest University School of Medicine, Winston-Salem, USA,6Public Health England, Oxford, UK,7Dept of Histopathology and Paediatric Laboratory Medicine, Great Ormond Street Hospital, London, UK,8Cancer Genetics Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
A randomised trial of interventions to increase uptake of cervical screening among 25 year old non-attenders; final results of the STRATEGIC Trial.
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Institute of Cancer Sciences, University of Manchester, Manchester, UK,2Institute of Population Health, University of Mancchester, Manchester, UK,3Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen, UK
Can WBRT be omitted in NSCLC patients with brain metastases not suitable for stereotactic radiosurgery or surgical resection? Results from the UK Medical Research Council QUARTZ randomised clinical trial.
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Northern Centre for Cancer Care, Newcastle upon Tyne, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Castle Hill Hospital, East Yorkshire, UK,4The Christie, Manchester, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6University Hospital Llandough, South Glamorgan, UK,7Royal Victoria Infirmary, Newcastle upon Tyne, UK,8Beatson West of Scotland Cancer Centre, Glasgow, UK,9Mater Hospital, Brisbane, Queensland, Australia,10Nottingham University Hospitals, Nottingham, UK,11Weston Park Hospital, Sheffield, UK,12Queen Elizabeth Hospital, King’s Lynn, UK
5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer [CRUK/06/016]: report from the CHHiP Trial Management Group
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1The Institute of Cancer Research, London, UK,2Clatterbridge Cancer Centre, Wirral, UK,3Velindre Cancer Centre, Cardiff, UK,4Ipswich Hospital, Ipswich, UK,5Lincoln County Hospital, Lincoln, UK,6Royal Surrey County Hospital, Guildford, UK,7Christie Hospital, Manchester, UK,8Royal Marsden NHS Trust, London, UK,9Musgrove Park Hospital, Taunton, UK,10Royal Sussex County Hospital, Brighton, UK,11Royal Preston Hospital, Preston, UK
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1The Christie NHS Foundation Trust, Manchester, UK,2National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan,3National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan,4HonorHealth, Scottsdale, AZ, USA,5TGen, Scottsdale, AZ, USA,6Taipei Veterans General Hospital, Taipei, Taiwan,7National Yang-Ming University, Taipei, Taiwan,8Washington University in St. Louis, St. Louis, MO, USA,9St László Teaching Hospital, Budapest, Hungary,10St John of God Hospital, Subiaco, Western Australia, Australia,11Scottsdale Healthcare, Scottsdale, AZ, USA,12Vall dHebron University Hospital, Barcelona, Spain,13Vall dHebron Institute of Oncology, Barcelona, Spain,14Seoul National University Hospital, Seoul, Republic of Korea,15Hôpital Saint-André, Bordeaux, France,16China Medical University Hospital, Taichung, Taiwan,17Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil,18Klinikum rechts der Isar der TU München, Munich, Germany,19Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA
CheckMate 025: a randomized, open-label, phase III study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
Year: 2015
Session type: Oral, Proffered paper sessions
1MD Anderson Cancer Center, University of Texas, Houston, TX, USA,2Institut Gustave Roussy, Villejuif, France,3Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA,4Roswell Park Cancer Institute, Buffalo, NY, USA,5Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA,6Stanford Cancer Institute, Stanford, CA, USA,7University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA,8Vanderbilt University Medical Center, Nashville, TN, USA,9Fondazione Istituto Nazionale Tumori, Milan, Italy,10Fox Chase Cancer Center, Philadelphia, PA, USA,11Hospital Universitario 12 De Octubre, Madrid, Spain,12Westmead Hospital, New South Wales, Australia,13Aarhus University Hospital, Aarhus, Denmark,14Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland,15South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK,16University Hospital Essen of University of Duisburg-Essen, Essen, Germany,17Chiba Cancer Center, Chiba, Japan,18Bristol-Myers Squibb, Hopewell, NJ, USA,19Bristol-Myers Squibb, Lawrenceville, NJ, USA
Physical activity levels and barriers to exercise referral among patients with cancer
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1University of Cambridge School of Clinical Medicine, Cambridge, UK,2Macmillan Cancer Support, London, UK,3Coventry University, Coventry, UK,4Addenbrookes Cambridge University Hospitals NHS Trust, Cambridge, UK,5Bedford Hospital NHS Trust, Bedford, UK
Effect of pre-diagnostic NSAID use on ovarian cancer survival
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1National Cancer Registry Ireland, Cork, Ireland,2Trinity College Dublin, Dublin, Ireland,3Newcastle University, Newcastle, UK
E-cadherin deficiency a novel determinant of ROS1 inhibitor sensitivity
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1ICR, LONDON, UK,2UCSF, SAN FRANCISCO, USA
MAMMO-50: The results of the pre-planned internal 2 year feasibility study for Mammographic surveillance in early breast cancer patients over 50 years of age at diagnosis
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Warwick Clinical Trials Unit, Coventry, UK,2South Devon Healthcare NHS Foundation Trust, Torquay, UK,3Independent Cancer Patient Voices, London, UK,4Department of Clinical Healthcare, Oxford Brookes University, Oxford, UK,5St James’s University Hospital, Leeds, UK,6University Hospital of South Manchester NHS Foundation Trust, Manchester, UK,7Ninewells Medical School, Dundee, UK
Targeted next-generation sequencing: cell-free DNA profiles mirror the heterogeneity of single CTCs
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Department of Cancer Studies and Cancer Research UK Leicester Centre, Leicester, UK,2Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK,3Silicon Biosystems, Bologna, Italy
The splicing inhibitor Spliceostatin A downmodulates Mcl-1 expression and induces a potent apoptotic response in Chronic Lymphocytic Leukaemia cells
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK,2Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK,3Cehmical Genomics Group, RIKEN Center for Sustainable Resource Science, Wako, Japan
CTEN (C-terminal Tensin-like) regulates head and neck cancer invasion and survival
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1University of Southampton, Southampton, UK,2University of Portsmouth, Portsmouth, UK,3St. George’s University Hospitals, London, UK,4Poole Hospital NHS Foundation Trust, Poole, UK
Signatures of ionising radiation in second malignancies
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Wellcome Trust Sanger Institute, Hinxton, UK,2Harvard Medical School, Boston, UK,3University of Tampere and Fimlab Laboratories, Tampere, Finland,4University College London, London, UK
A National Platform for Molecular Diagnostics: Results from Phase I of the Cancer Research UK Stratified Medicine Programme
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Cancer Research UK, London, UK,2Cancer Research UK Cambridge Institute, Cambridge, UK,3Institute of Medical Genetics, Cardiff, UK,4University of Oxford, Oxford, UK,5The Centre for Molecular Pathology, Surrey, UK,6West Midlands Regional Genetics Laboratory, Birmingham, UK,7Leeds Institute of Cancer and Pathology, Leeds, UK,8University of St. Andrews, St. Andrews, UK,9The Royal Marsden NHS Foundation Trust, London, UK,10Cardiff University, Cardiff, UK,11The Queen Elizabeth Hospital, Birmingham, UK,12Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK,13NHS Greater Glasgow and Clyde, Glasgow, UK,14Papworth Hospital NHS Foundation Trust, Cambridge, UK,15Manchester Cancer Research Centre, Manchester, UK
Real-Time Diagnosis of Ovarian Cancer with the Surgical Intelligent Knife (iKnife)
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1Imperial College, London, UK,2Waters Corporation, Budapest, Hungary
Variations in GPs Decisions to Investigate Suspected Lung Cancer: A Factorial Experiment Using Multimedia Vignettes
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1UCL, London, UK,2QMUL, London, UK,3University of Exeter, Exeter, UK,4London Borough of Waltham Forest, London, UK
Children’s Cancer and Leukaemia Group (CCLG) McElwain Award winner – Adamantinomatous craniopharyngioma contains senescent cells with tumour-inducing potential
Year: 2015
Session type: Oral, Parallel sessions, Proffered paper sessions
1University College London, London, UK,2University of Oxford, Oxford, UK,3Imperial College London, London, UK,4King’s College London, London, UK,5Great Ormond Street Hospital, London, UK